Podcasts about tumors

Amy’s son is dealing with an injury causing him tons of pain and needs our help. Eddie has great news on his mom’s recovery from having a tumor removed. Lunchbox got his 4th PRP shot or at least we think it was a PRP shot. We investigate what was put into his body. Bobby talks about having a busy but good day yesterday with his friend Brett Eldredge. Raymundo has an update on the Pop-A-Shot machine delivery.See omnystudio.com/listener for privacy information.

Eine Rücken-OP, Lähmung, Reha – wie sich Anna-Lena Niehues, Reitlehrerin und Parareiterin, nach einem Tumor in der Halswirbelsäule Schritt für Schritt in den Sport zurück gekämpft hat. Interview: Monika Kursawe.

Broadcast from KSQD, Santa Cruz on 8-13-2026: Dr. Dawn opens by reading an anatomy student's elegy to a body donor, reflecting on how modern medical education has moved away from full cadaver dissection toward pre-dissected specimens and models—and what she believes has been lost in that transition. Dr. Dawn dissects how hospital consolidation has become the primary driver of runaway U.S. healthcare costs. She contrasts a $16,000 knee replacement at Catawba Valley Medical Center with a $40,000 procedure for the same Blue Cross Blue Shield plan an hour away at Asheville's Mission Hospital—a facility formed by the 1998 merger of the town's two acute-care hospitals and later acquired by HCA in 2018. Mission now charges 333% of Medicare rates (versus a 280% benchmark), and state inspectors have issued three "immediate jeopardy" findings since HCA's takeover, consistent with academic findings that hospital care quality drops when competition disappears. She notes that CMS-required price disclosures since 2021 finally make this transparent, and calls for regulatory prevention of hospital mergers—especially not-for-profit to for-profit conversions—in single or two-hospital markets. Dr. Dawn analyzes the 3.1% year-over-year drop in prescription drug prices reported through July—the sharpest decline since 1963. She attributes most of it to Biden's 2022 Inflation Reduction Act, which partially rescinded George W. Bush-era Medicare Part D restrictions that had statutorily prohibited price negotiation, saving taxpayers roughly $6 billion in the first six months of implementation. Additional contributors include GLP-1 compounding competition, blockbuster drugs losing exclusivity, and Bureau of Labor Statistics methodology that swaps generics into the price index six months after brand patent expiration. She calls for consumer-facing apps that help patients shop hospital prices the same way they shop cars. Dr. Dawn covers the emerging science of dormant tumor cells—cancer cells that shed from primary tumors even before diagnosis, hide in bone marrow and lymph nodes, and enter a hibernation state (feeding off cellular residue via autophagy) that shields them from chemotherapy targeting rapidly dividing cells. New York researchers have identified proteins by which lung macrophages actively reinforce dormancy, but immune disruption from COVID-19, influenza, aging, and chronic stress can trigger reactivation. She emphasizes lifestyle protection for cancer survivors: minimal alcohol, Mediterranean diet, and five daily cups of green tea for the EGCG dormancy-maintaining effect seen in cell culture. A caller argues for single-payer healthcare and questions whether Medigap insurance is worth $287 monthly. Dr. Dawn explains the math: for a $100,000 hospital bill, 20% coinsurance is $20,000, making the $2,400 annual premium reasonable catastrophic-risk protection—though skipping it is a defensible bet for very low-utilization patients. She notes those whose income drops to Medi-Cal eligibility often end up with better coverage than middle-class seniors. The same caller then presents a differential diagnosis of himself as likely multiple sclerosis based on ChatGPT consultation, describing balance loss requiring hallway wall-guidance, dramatic vision changes, and fasciculations. Dr. Dawn walks through prompt engineering for medical AI: request differential lists ordered by probability of frequency in the population rather than symptom-fit alone. She notes symmetric symptoms argue against MS, suggests checking electrolytes (particularly calcium), and emphasizes that a physical examination should precede imaging to avoid incidentalomas that trigger cascading invasive workups—cautioning that without a primary care doctor, he lacks an advocate within the system.

In today's Beating Cancer Daily episode, Saranne explores creating a living legacy with excitement and optimism. As someone who has beaten Stage IV cancer for 30 years, Saranne shares her perspective on why it's essential to consciously think about and enjoy crafting a legacy, regardless of the timeline we have. Join her as she discusses fun and creative ways to leave a lasting imprint, from recording books for loved ones to planting living markers of our time. Get ready to be inspired and discover how embracing the concept of legacy can bring joy and depth to our lives as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

The Nurses Report on America Out Loud with Ashley Caputo, RN, FMP – We explore the remaining Terrain Ten factors, examining immune regulation, inflammation, circulation, hormones, biorhythms, stress, and emotional health while showing how interconnected systems shape whole-person cancer support, resilience, patient advocacy, and informed healthcare decisions beyond focusing solely on the tumor itself...

The Nurses Report on America Out Loud with Ashley Caputo, RN, FMP – We explore the remaining Terrain Ten factors, examining immune regulation, inflammation, circulation, hormones, biorhythms, stress, and emotional health while showing how interconnected systems shape whole-person cancer support, resilience, patient advocacy, and informed healthcare decisions beyond focusing solely on the tumor itself...

Warum alte Pflanzensorten die Ernährung sichern könnten ; Wie Transporte vom Fluss auf die Straße kommen ; Kann Virtual Reality die Klimakrise fühlbar machen? ; Große Fragen in zehn Minuten: Beeinflusst Sprache unser Handeln? ; So wichtig ist Feinmotorik für schulischen Erfolg von Kindern ; Mit Zellen gegen Nierenkrebs - Fortschritt in Krebsmedizin ; Moderation: Marija Bakker. Von WDR 5.

We love to hear from our listeners. Send us a message.In Episode 135 of Cell & Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, about the company's novel approach to treating solid tumors by engineering regulatory T cells (Tregs) rather than conventional effector immune cells. Dr. Gupta explains how CoRegen's investigational cell therapy, CRG150, targets the upstream regulator SRC3 to simultaneously influence multiple immune checkpoint pathways. She also discusses the scientific rationale behind the platform, the transition into first-in-human clinical studies, the biomarkers and translational questions the company hopes to answer, and why manufacturing, CDMO selection, and chain-of-identity capabilities are foundational to the future success of autologous cell therapies.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Die "Hölle-AGBs" - so nennt Martin Thoms die Glaubenssätze, die ihm in einigen christlichen Gemeinschaften immer wieder begegnen. Warum er diese mit einem Tumor vergleicht und wie er sie gerade mit Theologie bekämpfen will, berichtet der Theologe, Prediger, Autor, Dozent und Berater in dieser Folge des yeet-Podcasts. Außerdem erzählt er, wie er die frohe Botschaft des Evangeliums in die Praxis übersetzt und an die Menschen bringt - auch mit Hilfe von Social Media. Und was der Prophet Amos mit all dem zu tun hat... Mehr zu Martin Thoms (dort findest du auch alle Podcasts und Blogs mit Martin aufgelistet): www.martinthoms.de Martin bei yeet: yeet.de/martin-thoms Martins Bücher: Zur Hölle mit der Hölle! Neukirchener Verlagsgesellschaft 2026 Die biblische Urgeschichte. Evangelische Verlagsanstalt 2026 100 Argumente für die Allversöhnung (E-Book) "Es ist vollbracht!" Oder doch nicht? Evangelische Verlagsanstalt 2025 Der gottverlassene Gott. Lit-Verlag 2025 Martins Coachingprogramm ab Herbst: ZEHN. Ein Jahr, das dich verändert Du kannst Martin auch jederzeit für Seminare, Workshops, Predigten oder Reden jeder Art einladen. Schreib ihm dazu einfach eine Mail an: kontakt@martinthoms.de Social Media für Glaube und Kirche - das ist der yeet-Podcast: yeet-Redakteur* innen befragen Expert* innen und Influencer* innen und begeben sich auf die Suche nach den großen und kleinen Perspektiven auf die digitalen Kirchen-Räume und Welten in den Sozialen Medien.

Colorectal cancer does not develop in isolation. Cancer cells exist within a complex tumor microenvironment made up of fibroblasts, immune cells, blood vessels, and extracellular matrix. Increasing evidence suggests that these surrounding cells and structures can influence whether tumors grow, regress, or evade the immune system. A research paper published in Volume 17 of Oncotarget, titled “Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer,” investigated the role of collagen triple helix repeat containing 1 (CTHRC1), a secreted protein found in cancer-associated stroma. Full blog post - https://www.oncotarget.org/2026/08/10/cthrc1-in-the-tumor-microenvironment-drives-colorectal-cancer-growth-in-mouse-study/ DOI - https://doi.org/10.18632/oncotarget.28878 Correspondence to: Sergey Ryzhov - Sergey.Ryzhov@mainehealth.org; Volkhard Lindner- Volkhard.Lindner@mainehealth.org; Michaela R. Reagan - Michaela.Reagan@mainehealth.org Abstract video - https://www.youtube.com/watch?v=gTbYy6vGd7E Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28878 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Cthrc1, CRC, colorectal cancer, subcutaneous tumor model, immune analysis To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Wann ist der richtige Zeitpunkt, ein geliebtes Tier gehen zu lassen? Diese Frage gehört wahrscheinlich zu den schwersten, die wir als Tierhalter jemals beantworten müssen. Oft ist es gar nicht nur die Angst vor dem Tod oder dem Verlust unseres Tieres. Es ist die Angst, eine falsche Entscheidung zu treffen. Habe ich mein Tier zu früh einschläfern lassen? Habe ich zu lange gewartet? Hätte ich noch etwas tun können? Und was denkt mein Tier darüber? Ist es vielleicht enttäuscht von mir? In dieser sehr persönlichen Folge des TierTalk Podcasts teile ich mit dir meine Erfahrungen aus über 20 Jahren Tierkommunikation und erzähle dir unter anderem von meinem Abschied von Felina. Ein Moment, vor dem ich mich lange gefürchtet hatte und der sich schließlich vollkommen anders angefühlt hat, als ich jemals erwartet hätte. Außerdem erzähle ich dir von einem Hund, bei dem zufällig ein Tumor entdeckt wurde und plötzlich das Thema Einschläfern im Raum stand, obwohl seine Menschen tief in sich spürten, dass der Zeitpunkt noch nicht gekommen war. In dieser Folge erfährst du, warum Angst unser eigenes Gefühl überlagern kann, weshalb ein schlechter Tag nicht automatisch bedeutet, dass dein Tier bereit ist zu gehen, und warum es so wichtig ist, neben einer guten tierärztlichen Begleitung auch die Verbindung zu deinem Tier und zu deinem eigenen Empfinden nicht zu verlieren. Denn unsere Tiere wünschen sich keinen perfekten Menschen. Sie wünschen sich einen Menschen, der auf sein Gefühl hört und sich selbst vertraut. Und vielleicht ist genau das beim Abschied eines der größten Learnings, das wir Menschen durch unsere Tiere erfahren dürfen. Wenn du gerade vor einem Abschied stehst, dein Tier bereits verloren hast oder Angst vor diesem Moment hast, dann lade ich dich am 24. August zu meinem Workshop „Für immer unzertrennlich“ ein. Dort gehen wir noch viel tiefer in dieses Thema und ich werde mit dir eine besondere Übung machen, die dir helfen kann, dein eigenes Gefühl wieder wahrzunehmen und Vertrauen zu finden.

Pathologen sind schrullige Typen, die im Tatort die Leichen aufschlitzen? Nicht vollkommen falsch, aber doch nur ein sehr kleiner Ausschnitt von dem, was Pathologen tatsächlich tun. Prof. Dr. Irina Berger ist Chefärztin der Pathologie am Klinikum Kassel. Sie versucht jeden Tag zu entschlüsseln, wie krankes Gewebe sich entwickelt, um mit diesem Wissen Tumore zu bekämpfen - und zwar passgenau für jeden Patienten. (Wdh. vom 18.09.2025)

Tumor shrinkage, long-term remissions, and radical recoveries—these stories reveal the real-world power of the Nutritarian diet. #CancerReversal #NutritarianSuccess #HealingStories #HealthTalks

This episode is sponosored by Hulu. Stream PRISON BREAK on Hulu in the U.S. and Disney+ Internationally. Sarah Wayne Callies and Paul Adelstein compare this episodes' stealthy Scylla-heist set pieces to Entrapment and Mission: Impossible, including trivia that the Mission: Impossible theme rhythm spells “M-I” in Morse code. They praise director Kevin Hooks' dynamic camera movement and staging, note the episode's original airdate (Nov. 17, 2008) and 5.5 million live viewers, and touch on 2008 music news (AC/DC's Black Ice; CMA and AMA winners). Their deeper conversation focuses on Michael's worsening brain tumor and the confusing logic of him avoiding the hospital while still doing intense physical work, plus “honeypot” seduction tactics failing for Gretchen (and earlier for Sara) but working better as a long con for Trishanne, leading into thoughts on Gretchen's trauma bond with the General. They also discuss gamma knife surgery, speculate whether the tumor storyline functioned as a possible behind-the-scenes “exit ramp” for Michael/Wentworth Miller while still serving the drama, and answer fan questions about Sara's evolving bond with Lincoln and whether Michael's refusal of surgery hurts Sara or reflects his stubborn hero complex. For the full experience of enjoying Prison Breaking With Sarah & Paul, subscribe to our Patreon channel where you can watch Sarah & Paul's running commentary on Ep 306 while re-watching the episode on Hulu or your home DVD collection. You can also watch in a group with other fans on our fan-led Discord server. Subscribe here: ⁠⁠⁠⁠https://patreon.com/user?u=116411884⁠⁠⁠⁠ -or- Click Link in Bio Patreon Subscribers get access to all of our Watch Parties and FanFiction (all captioned in six languages - English, French, Spanish, German, Portuguese, and Turkish), exclusive Ask Me Anything's with Sarah & Paul, and unannounced Discord drop-ins on our always rollicking server with fans and friends who come together from around the world. All for less than a cup of coffee. Leave us your comments, shoot us an email, or leave us a voicemail - we love hearing from all of you! prisonbreaking@caliber-studio.com (401) 3-PBREAK Watch the episode on YouTube - / @prisonbreakpodcast Follow us on Instagram - / prisonbreakpodcast Follow us on TikTok - / prisonbreakpodcast Merch!!! - https://pbmerch.printify.me/products #fyp #michaelscofield #saratancredi #michealscofield #prisonbreakedits #prisonbreak #wentworthmilleredits #wentworthmiller #editor #fyy #fyppp #saratancrediedit #prisonbreakseason1 #sarahwaynecallies #prisonbreakseason2 #scofield #fy #sarascofield #saratancrediedits #scofield Logo design by John Nunziatto @ Little Big Brands. If you want one yourself, reach out at https://www.littlebigbrands.com/ and tell him we sent you. PRISON BREAKING WITH SARAH & PAUL is a Caliber Studio production. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, Saranne delves into the world of tumor humor as she reflects on her experience with hair loss during her cancer journey. As a survivor, Saranne understands the emotional impact of losing hair during cancer treatment and shares how she approached this challenging experience with a comic perspective. Join her as she discusses the humorous side of coping with hair loss and invites listeners to participate in creating their tumor humor. Prepare for a lighthearted and insightful discussion on finding laughter in the face of adversity as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Brain cancers are rare, but devastating. Patients face short life expectancies after diagnosis. Brain tumors are often impossible to remove completely. And radiation and chemotherapy don't always stop them from spreading.  It's a daunting class of disease to study, but that didn't dissuade Michelle Monje from trying. She has spent two decades studying how brain tumors form and interact with healthy brain cells, and pioneered the field of cancer neuroscience.  Guest: Dr. Michelle Monje is a professor of pediatric neuro-oncology at Stanford Medicine.  Other episodes you may enjoy: Promising new treatments for pancreatic cancer and ALS The new frontier of cancer research is in space Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today on Beating Cancer Daily, Saranne, the founder of the ComedyCures Foundation and a Stage IV cancer survivor for over 30 years, brings a much-needed lighthearted perspective to the realities of life with cancer. Through her signature humor and wisdom, she shares a laugh-out-loud colonoscopy joke and introduces listeners to the 31-Day Tumor Humor Challenge, designed to help reframe stressful cancer experiences. Saranne also discusses an inspiring Etsy poster that lists things we simply cannot control, encouraging listeners to identify and release these burdens, thereby finding greater healing and joy. With personal anecdotes about the controversial yet deeply meaningful decisions she made throughout her cancer journey, Saranne reminds everyone that humor and self-reflection go a long way in cultivating resilience on the toughest days.“My colonoscopy just confirmed that I'm beautiful inside and out.” ~Saranne2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

En este episodio de pódcast, el Dr. Antonio Martín Benlloch, jefe de la Unidad Multidisciplinar de Patología Vertebral, unidad de referencia del Hospital Universitario Dr. Peset de Valencia, aborda la importancia de la biopsia previa antes de decidir el tratamiento y la planificación quirúrgica en tumores vertebrales malignos y metástasis. Advierte que cada vez se diagnostican más casos en pacientes jóvenes, que pueden pasar desapercibidos en urgencias, y subraya la necesidad de recurrir a centros de referencia, incluso internacionales, para minimizar riesgos para el paciente y maximizar el beneficio de la resección tumoral.

BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta Cancer Center at Brown University. Patients who develop multiple primary cancers face unique diagnostic and treatment challenges because each tumor may have distinct biological characteristics requiring different therapeutic approaches. Advances in genomic profiling and precision oncology now enable clinicians to better distinguish between independent tumors and recurrent disease while identifying molecular alterations that may guide individualized treatment strategies. This case report demonstrates how an international molecular tumor board integrated comprehensive genomic data with multidisciplinary expertise to develop personalized recommendations for a patient with an exceptionally complex cancer history. The case describes the clinical journey of a 48-year-old woman carrying a germline BRCA1 mutation who developed multiple primary cancers over nearly two decades, including breast cancer, basal cell carcinoma of the skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel adenocarcinoma. During this time, she underwent multiple surgeries, chemotherapy regimens, targeted therapy with the PARP inhibitor niraparib, and extensive molecular testing to characterize each malignancy. Full press release - https://www.oncotarget.com/news/pr/international-molecular-tumor-board-explores-personalized-treatment-strategies-for-a-patient-with-multiple-primary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28899 Correspondence to - Wafik S. El-Deiry - wafik_el-deiry@brown.edu Abstract video - https://www.youtube.com/watch?v=4KIDbmq6ui8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28899 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Ryan Beal, Founder and CEO of Dyve Biosciences, has developed a transdermal delivery approach that uses the skin to deliver agents into circulation, where they selectively neutralize the acidic tumor microenvironment. By correcting acidity, the immune system is reactivated to better recognize and attack cancer cells, as acidity serves as a natural immune checkpoint that allows tumors to evade immune surveillance. Unlike previous oral delivery approaches that cause gastrointestinal side effects, this non-invasive lotion-based technology delivers the same pharmaceutical safety and efficacy. Ryan explains, "What led me there is that tumor acidity has driven cancer biology for decades. The science has settled. What was missing was a way to actually fix it in patients and do it safely, broadly, and at scale. And that's what Dyve built. In 2026, the goal is to bring it into humans with trials at Moffitt Cancer Center."   "The core at Dyve was developing the delivery system. It could bring molecules through the skin. And one of the approaches that we got quite excited about early on was delivering buffering agents through the skin. The natural application was in oncology and going after the acidity of the tumor microenvironment."   "So it's a topical. In many ways it will look and feel like a lotion, and it's applied to the skin but delivered systemically. So we're essentially turning the skin into a delivery portal for these drugs. And that's important, especially important in the case of tumor acidity.  Because we and others have shown that while in animals you can deliver these therapies orally, it's a big delivery challenge for humans to take these agents orally. So you needed another way to circumvent those problems, and the skin gave us a really convenient path to do that." #DyveBiosciences #MoffittCancerCenter #CancerResearch #Oncology #CancerTreatment #Immunotherapy #PrecisionMedicine #DrugDevelopment #ClinicalTrials #TumorMicroenvironment #TransdermalDelivery #Biotechnology #OncologyInnovation #TransdermalTherapy #DrugDelivery #CancerCare #HealthcareInnovation DyveBio.com Download the transcript here

Dr. Ryan Beal, Founder and CEO of Dyve Biosciences, has developed a transdermal delivery approach that uses the skin to deliver agents into circulation, where they selectively neutralize the acidic tumor microenvironment. By correcting acidity, the immune system is reactivated to better recognize and attack cancer cells, as acidity serves as a natural immune checkpoint that allows tumors to evade immune surveillance. Unlike previous oral delivery approaches that cause gastrointestinal side effects, this non-invasive lotion-based technology delivers the same pharmaceutical safety and efficacy. Ryan explains, "What led me there is that tumor acidity has driven cancer biology for decades. The science has settled. What was missing was a way to actually fix it in patients and do it safely, broadly, and at scale. And that's what Dyve built. In 2026, the goal is to bring it into humans with trials at Moffitt Cancer Center."   "The core at Dyve was developing the delivery system. It could bring molecules through the skin. And one of the approaches that we got quite excited about early on was delivering buffering agents through the skin. The natural application was in oncology and going after the acidity of the tumor microenvironment."   "So it's a topical. In many ways it will look and feel like a lotion, and it's applied to the skin but delivered systemically. So we're essentially turning the skin into a delivery portal for these drugs. And that's important, especially important in the case of tumor acidity.  Because we and others have shown that while in animals you can deliver these therapies orally, it's a big delivery challenge for humans to take these agents orally. So you needed another way to circumvent those problems, and the skin gave us a really convenient path to do that." #DyveBiosciences #MoffittCancerCenter #CancerResearch #Oncology #CancerTreatment #Immunotherapy #PrecisionMedicine #DrugDevelopment #ClinicalTrials #TumorMicroenvironment #TransdermalDelivery #Biotechnology #OncologyInnovation #TransdermalTherapy #DrugDelivery #CancerCare #HealthcareInnovation DyveBio.com Listen to the podcast here

Circulating tumor DNA (ctDNA), a minimally invasive blood-based biomarker, has emerged as one of the most promising advances in cancer surveillance. Today, we will explore how ctDNA is transforming the management of colorectal cancer and anal squamous cell cancer across the disease continuum—from risk stratification and adjuvant therapy decision-making to surveillance and early detection of recurrence. Through landmark clinical trials, real-world applications, and emerging research, we will examine how ctDNA is helping move cancer care closer to the goal of truly personalized medicine.Hosts: ·       Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center·       Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian·       Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital·       Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer CenterGuests:Dr. Paul Romessor ·      Director of Colorectal and Anal Cancer, Department of Radiation Oncology·      Associate Attending Radiation OncologistMemorial Sloan Kettering Cancer CenterDr. Jeanne Tie ·      Medical Oncologist | Lower GI Unit ·      Lower GI Research Lead ·      Chair | Lower GI Working Party | GI Cancer TrialsPeter MacCallum Cancer Centre Dr. Takayuki Yoshino·      Professor, Global Center of Research Excellence for Advanced Medicine (G-CORE),Keio University School of Medicine·      Executive Advisor to Hospital East Director·      Director, Department of Global Oncology·      Chief, Department of Gastrointestinal OncologyNational Cancer Center Hospital EastLearning Objectives:·      Describe the biological basis and clinical applications of circulating tumor DNA (ctDNA) as a biomarker of minimal residual disease (MRD) in colorectal cancer.·      Interpret the prognostic significance of postoperative and longitudinal ctDNA testing and its role in predicting recurrence risk across stages of colorectal cancer.·      Evaluate evidence from landmark clinical trials, including DYNAMIC and GALAXY, supporting ctDNA-guided treatment de-escalation and escalation strategies in colorectal cancer.·      Discuss emerging applications of ctDNA monitoring in personalized cancer care, including surveillance, treatment response assessment, and future clinical trial directions. References:·      Ando, K. et al. (2026). Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study. Annals of Surgery. https://pubmed.ncbi.nlm.nih.gov/39854721/ (Note: If direct access is limited, the article is available via PMC: PMC12695342)·      Romesser, P. B. et al. (2026). Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38347209/·      Tie, J. et al. (2025). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39943485/·      Tie, J. et al. (2025). Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39974258/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Aunque tiene 70 años de carrera y desde hace dos necesita un doble trasplante de pulmón, Jorge Ortiz de Pinedo se mantiene activo en el medio artístico donde debutó a los ocho años, a instancias de sus padres Don Oscar Ortiz de Pinedo y de su madre Lupita Pallás.

Rebecca's story is one of extraordinary resilience. What began as a routine induction quickly turned into a life-threatening postpartum emergency, followed by the discovery of a rare orbital tumor, multiple surgeries, and a long road through PTSD and healing. In this heartfelt Listener Series episode, Rebecca shares how community, therapy, faith, and giving back helped her reclaim her life after birth trauma. If you've ever felt like your trauma became your identity, this conversation offers hope that healing is possible, even if it takes time.In this episode, we discuss:✨ Rebecca's difficult second pregnancy and the unexpected vision changes that led to the discovery of an orbital tumor

Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgrThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc; Lilly; Nuvation Bio; Revolution Medicines, Inc; and Rigel Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

When we talk about EMF and cancer, the conversation usually focuses on risk. But what if electromagnetic fields could actually help treat cancer? In this episode, I break down a fascinating new study showing how pulsed electromagnetic field therapy altered the genetic profile of bladder cancer cells in the lab -- and what this tells us about the complex relationship between EMF and human biology. This isn't about fear. It's about understanding how the same technology that requires caution in one context might offer therapeutic benefits in another. In This Episode How pulsed electromagnetic fields changed gene expression in bladder cancer cells Why the same technology that poses risks can also treat disease What FDA-approved cancer treatments already use electromagnetic fields The key difference between therapeutic EMF and everyday exposure Featured Study Read the full study: Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer Cell Line HT-1197 See all studies at shieldyourbody.com/research

Reciben a 656 mexicanos deportados de EE. UU.  Protestas en Maine tras operativo del ICE  Francia le dio al mundo el sistema métrico   Más información en nuestro podcast#grc

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in molecular testing have transformed the management of these tumors, allowing clinicians to tailor treatment based on each patient's genetic profile. A case report published in Volume 17 of Oncotarget, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report,” describes an exceptionally rare case involving a patient whose tumor carried two genetic alterations that are traditionally considered mutually exclusive. Full blog post - https://www.oncotarget.org/2026/07/13/rare-genetic-combination-in-gastrointestinal-tumor-offers-new-insights-into-precision-cancer-care/ DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28863 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This episode is sponosored by Hulu. Stream PRISON BREAK on Hulu in the U.S. and Disney+ Internationally. Sarah Wayne Callies and Paul Adelstein discuss Prison Break episode 407, “Five the Hard Way,” opening with an explanation of the craps term “hard way” before reflecting on the production's Las Vegas shoot at the newly opened Planet Hollywood, including staying and filming on-site, the surreal “bubble” of casino life, and practical details like overheated door handles and early-morning casino atmosphere. They highlight comedic beats (including the Carrot Top gag), wardrobe and continuity decisions around Sara's outfits and scars, and debate story choices such as Sara's repeated honeypot attempts and the episode's “gay panic” pivot to Sucre, criticizing its logic and gender imbalance while noting how such writing would differ today. Callies shares a vivid on-set memory tied to postpartum depression, describing how it affected her behavior, went unrecognized for years, and later improved after seeking acupuncture and herbal support. They also touch on T-Bag and Gretchen's dynamic and briefly discuss TV scoring trends and how music guides audience engagement. For the full experience of enjoying Prison Breaking With Sarah & Paul, subscribe to our Patreon channel where you can watch Sarah & Paul's running commentary on Ep 306 while re-watching the episode on Hulu or your home DVD collection. You can also watch in a group with other fans on our fan-led Discord server. Subscribe here: ⁠⁠⁠⁠https://patreon.com/user?u=116411884⁠⁠⁠⁠ -or- Click Link in Bio Patreon Subscribers get access to all of our Watch Parties and FanFiction (all captioned in six languages - English, French, Spanish, German, Portuguese, and Turkish), exclusive Ask Me Anything's with Sarah & Paul, and unannounced Discord drop-ins on our always rollicking server with fans and friends who come together from around the world. All for less than a cup of coffee. Leave us your comments, shoot us an email, or leave us a voicemail - we love hearing from all of you! prisonbreaking@caliber-studio.com (401) 3-PBREAK Watch the episode on YouTube - / @prisonbreakpodcast Follow us on Instagram - / prisonbreakpodcast Follow us on TikTok - / prisonbreakpodcast Merch!!! - https://pbmerch.printify.me/products #fyp #michaelscofield #saratancredi #michealscofield #prisonbreakedits #prisonbreak #wentworthmilleredits #wentworthmiller #editor #fyy #fyppp #saratancrediedit #prisonbreakseason1 #sarahwaynecallies #prisonbreakseason2 #scofield #fy #sarascofield #saratancrediedits #scofield Logo design by John Nunziatto @ Little Big Brands. If you want one yourself, reach out at https://www.littlebigbrands.com/ and tell him we sent you. PRISON BREAKING WITH SARAH & PAUL is a Caliber Studio production. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Darryl S. Chutka, M.D.  Guests: Jake Eide, M.D. & Rijul Kshirsager, M.D.  Skull base tumors are not commonly seen in a primary care practice, yet it's important for us to recognize them when they do present. These tumors can be either benign or malignant, however because of their proximity to important structures in the brain, even benign tumors can cause serious complications. Their presentation can be subtle, and they are frequently mistaken for other more commonly seen health problems. Which presenting symptoms should give us concern? What are some common physical exam findings associated with these tumors, and what's the best initial imaging study to order? These are some of the questions I'll be asking my guests, Dr. Jake Eide and Dr. Rijul Kshirsagar, both surgeons in the Department of Otorhinolaryngology at the Mayo Clinic as we tackle “Skull Base Tumors.”  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

BUFFALO, NY – July 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on July 2, 2026, titled “Renal oncocytoma: Α case report and literature review.” The study was led by first and corresponding author Areti Kalfoutzou from the Second Propaedeutic Department of Internal Medicine, Attikon General Hospital, National and Kapodistrian University of Athens, Greece. Renal oncocytoma is a rare benign tumor of the kidney that accounts for approximately 5–9% of renal epithelial tumors. Although it is considered benign, it often resembles kidney cancer on imaging studies, making accurate diagnosis challenging. Because treatment strategies differ substantially between benign oncocytoma and malignant renal tumors, establishing the correct diagnosis is essential to avoid unnecessary surgery while ensuring appropriate patient care. In this report, the researchers describe the case of an 82-year-old woman who presented with two months of gross hematuria. Contrast-enhanced computed tomography (CT) identified a 55 × 34 mm exophytic lesion arising from the upper pole of the left kidney. Based on its imaging characteristics, the mass was initially classified as a Bosniak category IV renal lesion, raising strong suspicion for renal malignancy. Full press release - https://www.oncotarget.net/2026/07/06/rare-benign-kidney-tumor-case-highlights-value-of-biopsy-and-minimally-invasive-treatment/ DOI - https://doi.org/10.18632/oncotarget.28893 Correspondence to - Areti Kalfoutzou - areti.kalfoutzou@haf.gr Abstract video - https://www.youtube.com/watch?v=C7TBLT3tbfA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28893 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cryoablation, image-guided biopsy, kidney neoplasms, minimally invasive surgery, renal oncocytoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

In this episode of It Takes Balls, Tony Florio shares one of the most unusual testicular cancer stories featured on the podcast. An attorney, husband, and father of two young kids, Tony was on paternity leave when he developed a persistent ache in his lower abdomen. There was no lump, no testicular pain, and no obvious signs of testicular cancer, just a nagging discomfort that refused to go away.After a CT scan revealed a large abdominal mass, doctors initially suspected a sarcoma or paraganglioma, two diagnoses with far different prognoses than testicular cancer. Even after a scrotal ultrasound came back normal, Tony continued searching for answers. Using AI tools to better understand his medical reports and advocating for additional testing, he pushed for tumor markers that ultimately helped point his medical team in a different direction.Tony underwent major surgery to remove a retroperitoneal mass, entering the operating room knowing he could potentially lose part of his colon or even a kidney. Fortunately, the surgery was successful, and pathology revealed what nobody initially expected: a germ cell tumor consisting primarily of teratoma, embryonal carcinoma, and yolk sac tumor components. Even more unusual, doctors never found a tumor in either testicle, leaving questions about whether his cancer represented a burned-out testicular cancer or a rare extragonadal germ cell tumor.The episode also explores the emotional side of facing cancer while raising two young children. Tony reflects on the fear of not being there for his family, the support he received from his wife, friends, and neighbors, and the faith that helped carry him through the most uncertain moments. He also discusses postoperative complications, including a painful pneumothorax that landed him back in the hospital, as well as the surprising recommendation from his tumor board.This conversation is a powerful reminder that testicular cancer symptoms don't always start in the testicle, that self-advocacy matters, and that sometimes the most important part of the journey is simply getting the right diagnosis. Whether you're navigating a recent diagnosis, interested in rare presentations of germ cell tumors, or looking for hope during surveillance, Tony's story offers insight, perspective, and encouragement.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyJoin The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.x.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Glioblastoma is considered one of the most aggressive brain cancers, with survival often limited to about a year, largely because tumors adapt by rewiring how they use nutrients and energy Tumors divert vitamin B3 (niacinamide) away from normal energy production into a pathway that supports their survival, suggesting a metabolic weakness that could potentially be targeted This altered pathway may drain key cellular resources, meaning cancer cells appear to burn through materials they need to grow, which may create an opportunity to disrupt their fuel supply In a Science Advances study, high-dose vitamin B3 therapy was associated with improved short-term outcomes in patients, with over 80% showing no disease progression at six months in early findings, along with stronger immune activity against tumors Supporting your body's energy production and immune response through diet, lifestyle, and structured nutrient intake may help influence the same metabolic systems cancer depends on

Immune discusses a snippet on how EBV infection alters the immunopeptidome and promotes multiple sclerosis, and a paper on head and neck cancers harboring bacteria that create an immunosuppressive environment and promote immunotherapy resistance. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server EBV, Golli-MBP presentation and multiple sclerosis (Cell, 2026) Intratumoral bacteria promote resistance to cancer immunotherapy (Nat Cancer, 2026) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

 My guest provides advanced, patient-centered care for stroke, brain aneurysms, and a wide range of neurovascular conditions. Dr. Liff is recognized for his expertise in both medical and catheter-based treatments, including procedures such as cerebral angiography, mechanical thrombectomy, aneurysm coiling and stenting, carotid stenting, and embolization for arteriovenous malformations and tumors.Dr. Liff completed his undergraduate studies in Cognitive Science at Johns Hopkins University, earned his medical degree from SUNY Upstate Medical University, and trained in Neurology at Albert Einstein College of Medicine, where he served as Chief Resident. He specialized in fellowships in Vascular Neurology at Mt. Sinai Hospital and Endovascular Neurosurgery at NYU Langone Medical Center.He has presented original research at major conferences and published it in respected journals. Dr. Liff is a senior member of the Society of Neurointerventional Surgery and is dedicated to serving patients throughout the Tri-State Area, performing procedures at leading hospitals such as St. Francis Hospital, NYU Langone Hospital Long Island, and Lenox Hill Hospital. https://jeremyliffmd.com/#homehttp://www.yourlotandparcel.orgSupport the show

In this episode, Saranne invites you to join her for a lighthearted and informative discussion on the importance of having our affairs in order, even before a cancer diagnosis. With her signature humor and personal anecdotes, Saranne emphasizes the importance of wills, healthcare proxies, and durable power of attorney, while also sharing a humorous joke and offering practical tips on finding legal assistance. Tune in to discover how laughter can be found even in serious topics and how taking care of our legal affairs can bring peace of mind during challenging times.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00) Desmoid Tumors — Dr Gounder (2:58) Soft Tissue Sarcoma — Dr Riedel (28:29) CME information and select publications

Highlights from the PER® CME activity "Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.Earn CME credit by completing the full accredited activity (available through June 26, 2027):https://www.gotoper.com/iog26endometrial-activityThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Eisai, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Learn about the Healing Power of Prolonged Fasting: HEREWhat if the secret to deep healing isn't doing more, but going further?Most people assume that repeating short fasts is just as powerful as completing one long fast. Stack enough three-day fasts together and you'll eventually get the same result, right?It's a reasonable assumption, but it may be costing you the deeper healing you're working so hard to reach.Dr. Katie breaks down something many people have never been taught: short fasts and prolonged fasts are not the same healing tool. Short fasts are genuinely valuable. They can support ketosis, lower insulin, improve metabolic flexibility, and put pressure on cancer cells. Dr. Katie does a three-day fast herself every month.But she says they stop short of the second tier.That second tier begins after the early detox window, when the body moves into a much deeper fasting state. Around day eight is the threshold where the fast stops being just a metabolic tool and begins to reveal a much deeper layer of healing. Dr. Katie believes most people never reach because they keep restarting the clock.Chapters:00:04:22 - Why Short Fasts Reset the Clock00:05:21 - Detox Starts After Day Four00:06:21 - Why Long Fasts Need Supervision00:07:23 - The Danger of Refeeding Wrong00:08:21 - The Magic of Day Eight00:09:31 - The Body Targets Damaged Tissue00:10:22 - When Tumor Shrinkage Becomes Possible00:12:17 - The Mind Finally Quiets00:13:20 - Healing Crises Begin00:16:49 - Why You Can't Stack Short Fasts00:17:32 - Cancer Deserves the Full Distance00:18:52 - The Brain Tumor That Disappeared00:19:45 - Why Refeeding Matters Most00:21:00 - Fasting Opens Emotional Healing00:23:19 - What Cancer Experts Would Do00:24:45 - Physical and Emotional Healing Arrive TogetherEvery time you break a fast, your body doesn't just pause. It resets. Dr. Katie uses one simple analogy that makes this clear, and once you hear it, the difference between stacking short fasts and completing a prolonged fast becomes hard to unsee.Press play to learn why Dr. Katie believes anyone fasting for cancer needs to understand the difference between stopping early and going the full distance.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

After experiencing a number of illness when he was 2 years old going into the spring of 2025, Caitlyn and CJ Jennings thought that their beloved son Brooks was experiencing normal illnesses that many toddlers may experience. Unfortunately that was not the case. Brooks was diagnosed with a Fusion Mesenchymal Tumor that was located in his lung and then spread to his Pelvic Bone. Brooks continued to feel well until August of last year when his health went downhill, leading to his passing on October 25th of 2025.

Send us Fan Mail"Who is your daddy, and what does he do?"Grab your juice boxes and secure your nap mats, because this week on Entertain This!, Mitch and Tom are going undercover. That's right—we're strapping on our holsters and heading into the high-stakes, high-caffeine world of 1990's Kindergarten Cop.Join us as we analyze Arnold Schwarzenegger's pivot from unstoppable cyborg assassin to... a man trying to manage a room full of toddlers. Does Arnie have the range, or are the kids actually the ones pulling the strings? We're breaking down the film's iconic quips, the jarring tonal whiplash between "gritty drug bust" and "finger painting," and why this movie remains an essential artifact of 90s cinema madness.Whether you have fond memories of this childhood staple or you're watching it for the first time with cynical adult eyes, this episode is a mandatory field trip.Tune in, settle down, and try to keep your hands to yourselves while you listen. And remember: You're not a patient boy!New episodes drop every Monday. Don't forget to rate, review, and subscribe—or we'll tell the principal. Support the show

Featuring an interview with Prof Bernd Kasper, including the following topics: Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00) Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04) Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58) Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19) CME information and select publications

Unprocessed red meat and cancer risk remains one of the most debated topics in nutrition science, partly because the evidence is often presented in overly simplistic terms. The key question is not whether to adopt a vague "balanced" position on red meat, but whether the evidence clearly identifies intake levels at which colorectal cancer risk increases and whether controlled human trials support plausible mechanisms for that risk. A second issue is whether claims that fibre, vegetables, or an otherwise "healthy diet" can neutralise high red meat intake are actually supported by the mechanistic evidence, or whether they overstate what dietary context can plausibly offset. In this episode, Danny and Alan examine the evidence base by moving beyond the usual epidemiology-only debate. They discuss why regional intake patterns and dose thresholds matter, then explore controlled human feeding studies showing how higher red meat intake can increase endogenous N-nitroso compound formation, faecal water genotoxicity, and other mechanistic biomarkers linked to colorectal carcinogenesis. Timestamps: [01:11] Defining the exposure and outcome [02:34] Carcinogen labels explained [07:54] Epidemiology and dose thresholds [14:04] Interpreting null findings [19:09] Bingham 1996 nitroso study [25:20] Hughes dose response trial [33:49] Cross 2003 heme iron mechanism [42:55] Fecal water genotoxicity [55:42] Tumor mutational signatures [59:38] What we can conclude now [01:04:10] Practical intake recommendations [01:08:41] Key ideas segment (premium-only) Links: Go to episode page (includes links to studies mentioned) Subscribe to Sigma Nutrition Premium Join the Sigma newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course

lucy.co/lemon use code lemon Learn more about your ad choices. Visit megaphone.fm/adchoices

An upcoming resupply mission will carry tumor samples to the International Space Station for research. Experiments in microgravity have yielded shocking results: Some tumors triple in size in just 10 days—the kind of growth that could take 10 years on Earth. What does that mean for science, and for astronauts?  Joining Ira to discuss this new frontier in cancer research are hematologist Catriona Jamieson and aerospace engineer Meenal Datta. Guests:  Dr. Catriona Jamieson is a hematologist at the UC San Diego Health Moores Cancer Center in California. Dr. Meenal Datta studies the physics of cancer at the University of Notre Dame's College of Engineering in Indiana. Other episodes you may enjoy: How A Fringe Idea Led To Lifesaving Cancer Treatments To Get Ready For Mars, NASA Studies How The Body Changes In Space Want SciFri gear? Check out our new shop! Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-4-SCIFRI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.